On August 5, MarkHelts (CEO Seungmin Lee) and CALICI (CEO Jaemoon Choi) signed a memorandum of understanding (MOU) to collaborate on AI-driven CAR-T therapies targeting solid tumors, as well as biosensors for infectious disease monitoring. The partnership aims to validate therapeutic targets and efficacy using advanced AI algorithms.

MarkHelts is focusing on three core areas: AAV gene therapies, CAR-T therapies for solid tumors, and automated AI/digital-twin manufacturing technologies. By joining forces with CALICI, which specializes in AI-based drug discovery platforms, the two companies will work together to advance gene therapy manufacturing, in-silico validation, and drug efficacy simulations.

Through this collaboration, both sides expect to accelerate innovation in biopharmaceutical development and strengthen the efficiency of next-generation therapy production.